Predictive biomarkers and companion diagnostics. The future of immunohistochemistry: "in situ proteomics," or just a "stain"?

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

13 citing papers in PubMed.

1. The role of deubiquitinating enzymes and their inhibitors in esophageal carcinoma (Review).International journal of oncology · 2026
   Review
2. Practical quantification of immunohistochemistry antigen concentrations and reaction-diffusion parameters.bioRxiv : the preprint server for biology · 2026
   Article
3. Immunohistochemistry (IHC) staining of in-vitro cancer cell-generated tumoroids.MethodsX · 2023
   Article
4. Cancer: A pathologist's journey from morphology to molecular.Medical journal, Armed Forces India · 2022
   Review
5. Cytogenetic and Biochemical Genetic Techniques for Personalized Drug Therapy in Europe.Diagnostics (Basel, Switzerland) · 2021
   Review
6. Discovery and Evaluation of Protein Biomarkers as a Signature of Wellness in Late-Stage Cancer Patients in Early Phase Clinical Trials.Cancers · 2021
   Article
7. mRNA profiling of a well-differentiated G1 pancreatic NET correlates with immunohistochemistry profile: a case report.BMC gastroenterology · 2021
   Article
8. Companion Diagnostics: State of the Art and New Regulations.Biomarker insights · 2021
   Review
9. Biomarkers: Opportunities and Challenges for Drug Development in the Current Regulatory Landscape.Biomarker insights · 2020
   Review
10. Exploring Protein⁻Protein Interaction in the Study of Hormone-Dependent Cancers.International journal of molecular sciences · 2018
    Review
11. Getting controls under control: the time is now for immunohistochemistry.Journal of clinical pathology · 2015
    Review
12. Epitope recognition in the human-pig comparison model on fixed and embedded material.The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society · 2015
    Article
13. Immunohistochemistry for an improved clinical workflow in the era of personalized melanoma therapy?Melanoma management · 2015
    Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

1 author.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as